Standout Papers

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment... 2009 2026 2014 2020 470
  1. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial (2009)
    Jeffrey L. Lennox, Edwin DeJesus et al. The Lancet

Immediate Impact

2 by Nobel laureates 9 from Science/Nature 63 standout
Sub-graph 1 of 20

Citing Papers

Mechanisms of long COVID and the path toward therapeutics
2024 Standout
Medical, surgical, and physical treatments for Parkinson's disease
2024 Standout
1 intermediate paper

Works of Peter Sklar being referenced

Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease
2017
Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies
2017

Author Peers

Author Last Decade Papers Cites
Peter Sklar 1729 1386 534 41 2.2k
I Ocaña 1018 400 209 88 2.3k
Robert Zangerle 831 687 370 81 2.3k
Rose V. Thomas 1326 1093 127 20 2.2k
S. A. Danner 1344 1664 349 46 2.5k
Marta Massanella 1098 1693 455 78 2.4k
Valerio Tozzi 1128 1175 616 38 1.6k
Carey L. Shive 552 907 625 45 2.2k
Aylin Yilmaz 1085 855 354 66 1.8k
Marshall W. Fordyce 1442 949 495 30 1.8k
E. Randall Lanier 1312 1339 262 39 1.8k

All Works

Loading papers...

Rankless by CCL
2026